Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Sofia Bruni"'
Autor:
Santiago Madera, Franco Izzo, María F. Chervo, Agustina Dupont, Violeta A. Chiauzzi, Sofia Bruni, Ezequiel Petrillo, Sharon S. Merin, Mara De Martino, Diego Montero, Claudio Levit, Gabriel Lebersztein, Fabiana Anfuso, Agustina Roldán Deamicis, María F. Mercogliano, Cecilia J. Proietti, Roxana Schillaci, Patricia V. Elizalde, Rosalía I. Cordo Russo
Publikováno v:
Cell Death and Disease, Vol 14, Iss 12, Pp 1-3 (2023)
Externí odkaz:
https://doaj.org/article/f97153e8a240450a80194174d2482fd7
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/89813db880f840c8a0fc442bdcdfa259
Autor:
Sofia Bruni, María Florencia Mercogliano, Florencia Luciana Mauro, Rosalia Inés Cordo Russo, Roxana Schillaci
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Immunotherapy has changed the course of cancer treatment. The initial steps were made through tumor-specific antibodies that guided the setup of an antitumor immune response. A new and successful generation of antibodies are designed to target immune
Externí odkaz:
https://doaj.org/article/4d70ef13a2ea4a8482ed0c83e7b1c776
Autor:
Sofia Bruni, Florencia L Mauro, Cecilia J Proietti, Rosalia I Cordo-Russo, Martin A Rivas, Gloria Inurrigarro, Agustina Dupont, Dario Rocha, Elmer A Fernández, Ernesto Gil Deza, Daniel Lopez Della Vecchia, Sabrina Barchuk, Silvina Figurelli, David Lasso, Adrián D Friedrich, María C Santilli, María V Regge, Gabriel Lebersztein, Claudio Levit, Fabiana Anfuso, Teresa Castiglione, Patricia V Elizalde, Maria F Mercogliano, Roxana Schillaci
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 3 (2023)
Background The success of HER2-positive (HER2+) breast cancer treatment with trastuzumab, an antibody that targets HER2, relies on immune response. We demonstrated that TNFα induces mucin 4 (MUC4) expression, which shields the trastuzumab epitope on
Externí odkaz:
https://doaj.org/article/260a8bffb8ab415c8e86847e61a3c8b1
Autor:
Santiago Madera, Franco Izzo, María F. Chervo, Agustina Dupont, Violeta A. Chiauzzi, Sofia Bruni, Ezequiel Petrillo, Sharon S. Merin, Mara De Martino, Diego Montero, Claudio Levit, Gabriel Lebersztein, Fabiana Anfuso, Agustina Roldán Deamicis, María F. Mercogliano, Cecilia J. Proietti, Roxana Schillaci, Patricia V. Elizalde, Rosalía I. Cordo Russo
Publikováno v:
Cell Death and Disease, Vol 13, Iss 5, Pp 1-14 (2022)
Abstract Triple-negative breast cancer (TNBC) is clinically defined by the absence of estrogen and progesterone receptors and the lack of membrane overexpression or gene amplification of receptor tyrosine kinase ErbB-2/HER2. Due to TNBC heterogeneity
Externí odkaz:
https://doaj.org/article/c5cf687b8b084672a59b0ffb44e8ef9e
Autor:
Sofia Bruni, Florencia Mauro, Cecilia Proietti, Rosalia Cordo-Russo, Mercogliano María Florencia, Roxana Schillaci
Publikováno v:
Cancer Research. 83:P1-11
Background. Clinical trials have demonstrated that trastuzumab deruxtecan (T-DXd) provides a durable responses for patients with HER2-positive and HER2 low metastatic breast cancer (BC). With T-DXd treatment, approximately 50% of patients with HER2+
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d406db271a1d28decf1944d2f2430002
https://doi.org/10.1158/1538-7445.sabcs22-p1-11-12
https://doi.org/10.1158/1538-7445.sabcs22-p1-11-12
Autor:
Roxana Schillaci, Sofia Bruni, Florencia Mauro, María F Mercogliano, Agustina Roldan-Deamicis, Cecilia J Proietti, Rosalía Cordo-Russo, Gloria Inurrigarro, Agustina Dupont, Carla Adami, Daniel Lopez Della Vecchia, Sabrina Barchuck, Silvina Figurelli, Ernesto Gil Deza, Sandra Ares, Felipe G Gercovich, Patricia V Elizalde
Publikováno v:
Cancer Research. 82:P5-13
Background HER2-positive (+) and triple negative breast cancer (TNBC) have the worst survival among BC. BC patients are treated with chemotherapy (CT) and/or radiotherapy (RT), and HER2+ BC patients also receive targeted therapies, such as trastuzuma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6ea5a7e8d26549966ddc698723e940da
https://doi.org/10.1158/1538-7445.sabcs21-p5-13-32
https://doi.org/10.1158/1538-7445.sabcs21-p5-13-32
Publikováno v:
Cancer Research. 83:2273-2273
Clinical trials showed that trastuzumab deruxtecan (T-DXd) provides durable responses for patients with HER2+ and HER2 low metastatic breast cancer (BC), determined by immunohistochemistry. Approximately 50% of patients with HER2+ metastatic BC were
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::928b480f218a6f64fa8ebdcd5040488f
https://doi.org/10.1158/1538-7445.am2023-2273
https://doi.org/10.1158/1538-7445.am2023-2273
Autor:
Sofia Bruni, Mara De Martino, Florencia Mauro, Maria Mercogliano, Cecilia Proietti, Rosalia Cordo-Russo, Patricia Elizalde, Roxana Schillaci
Publikováno v:
Regular and Young Investigator Award Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::64112cffa49789a21d47bf65439b18a9
https://doi.org/10.1136/jitc-2022-sitc2022.0877
https://doi.org/10.1136/jitc-2022-sitc2022.0877
Autor:
Sofia Bruni, Florencia L. Mauro, Maria F. Mercogliano, Cecilia J. Proietti, Carla Adami, Agustina Dupont, Gloria Inurrigarro, Rosalia Cordo Russo, Patricia V. Elizalde, Roxana Schillaci
Publikováno v:
Cancer Research. 82:2047-2047
HER2+ is a breast cancer (BC) subtype characterized by the overexpression/amplification of HER2. Patients receive trastuzumab (Tz) but many (27-42%) do not achieve an objective response. We demonstrated that the overexpression of TNFɑ induces Tz res
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::17f583939b3bf11009d4ea630e781794
https://doi.org/10.1158/1538-7445.am2022-2047
https://doi.org/10.1158/1538-7445.am2022-2047